Bicara Therapeutics (NASDAQ:BCAX) Given New $37.00 Price Target at BTIG Research

Bicara Therapeutics (NASDAQ:BCAX) had its price target decreased by investment analysts at BTIG Research from $39.00 to $37.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research‘s price target would indicate a potential upside of 270.74% from the company’s current price.

BCAX has been the topic of several other reports. Wedbush decreased their price target on shares of Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating on the stock in a research note on Thursday, October 29th. Citigroup restated a “market outperform” rating on shares of Bicara Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.73.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $9.98 on Tuesday. The business has a fifty day moving average price of $17.89 and a 200 day moving average price of $20.91. The company has a market cap of $660.38 million, a P/E ratio of -3.22 and a beta of -0.33. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22). As a group, sell-side analysts predict that Bicara Therapeutics will post -3.49 EPS for the current fiscal year.

Insider Activity

In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently modified their holdings of BCAX. Siren L.L.C. raised its stake in Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares during the period. BlackRock Inc. purchased a new stake in shares of Bicara Therapeutics in the 2nd quarter valued at approximately $114,250,000. Jupiter Topco LLC acquired a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $93,957,000. Janus Henderson Group PLC increased its holdings in shares of Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after buying an additional 692,933 shares during the last quarter. Finally, Palo Alto Investors LP acquired a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $16,341,614.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.